Role of purinergic signalling and cytokines in the ischaemic stroke;Rola sygnalizacji purynergicznej i cytokin w indukcji procesów zapalnych w udarze niedokrwiennym mózgu

Aktualnosci Neurologiczne

Volumn 12, Issue 4, 2012, Pages 205-214

  Cieślak, Marek ^a  

^a Wojewódzki Szpital Zespolony W Toruniu ^*  (Poland)

Author keywords

Cytokines; Ischaemic stroke; Nucleosides; Nucleotides; Purinergic receptors

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; CYTOKINE; NUCLEOTIDE; PURINE;

ARTICLE; BRAIN ISCHEMIA; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; HUMAN; SIGNAL TRANSDUCTION;

EID: 84888231361     PISSN: 16419227     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (109)

1. Wardas J.: Neuroprotective role of adenosine in the CNS. Pol. J. Pharmacol. 2002; 54: 313-326.
2. Frizzo M., Lara D., Dahm K. i wsp.: Activation of glutamate uptake by guanosine in primary astrocyte cultures. Neuroreport 2001; 12: 879-881.
3. Stone T.W., Ceruti S., Abbracchio M.P.: Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb. Exp. Pharmacol. 2009; 193: 535-587.
4. Jarvis G.E., Humphries R.G., Robertson M.J., Leff P.: ADP can induce aggregation of human platelets via both P2Y1 and P2T receptors. Br. J. Pharmacol. 2000; 129: 275-282.
5. Cieślak M., Komoszyński M.: Rola i potencjalne znaczenie terapeutyczne nukleotydów i nukleozydów w udarze niedokrwiennym mózgu. Aktualn. Neurol. 2004; 4: 126-131.
6. Gachet C., Hechler B., Léon C. i wsp.: Activation of ADP receptors and platelet function. Thromb. Haemost. 1997; 78: 271-275.
7. Gachet C.: ADP receptors of platelets and their inhibition. Thromb. Haemost. 2001; 86: 222-232.
8. Hechler B., Eckly A., Ohlmann P. i wsp.: The P2Y1 receptor, necessary but not sufficient to support full ADP-inducted platelet aggregation, is not the target of the drug clopidogrel. Br. J. Haematol. 1998; 103: 858-866.
9. Storey R.F., Sanderson H.M., White A.E. i wsp.: The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br. J. Haematol. 2000; 110: 925-934.
10. Gachet C.: P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal. 2012; 8: 609-619.
11. Burnstock G.: Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007; 87: 659-797.
12. Burnstock G., Krügel U., Abbracchio M.P., Illes P.: Purinergic signalling: from normal behaviour to pathological brain function. Prog. Neurobiol. 2011; 95: 229-274.
13. Di Iorio P., Ballerini P., Traversa U. i wsp.: The antiapoptotic effect of guanosine is mediated by the activation of the PI 3-kinase/AKT/PKB pathway in cultured rat astrocytes. Glia 2004; 46: 356-368.
14. Burnstock G.: Purinergic nerves. Pharmacol. Rev. 1972; 24: 509-581.
15. Burnstock G.: Purine-mediated signaling in pain and visceral perception. Trends Pharmacol. Sci. 2001; 22: 182-188.
16. Cieślak M.: Badania ektopuryn i ektopirymidyn w płynie mózgowo-rdzeniowym u chorych z udarem niedokrwiennym mózgu o róznej etiologii. Rozprawa na stopień doktora nauk medycznych. Wojskowy Instytut Medycyny Lotniczej w Warszawie, Warszawa 2009.
17. Cieślak M., Mosińska J., Komoszyński M.: Changes in concentration of nucleotidic and nucleosidic agonist of P receptor in cerebrospinal fluid (CSF) of patients with neurological disorders. Eur. J. Neurol. 2004; 11 (supl. 2): 221.
18. Czarnecka J., Cieślak M., Komoszyński M.: Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 822: 85-90.
19. Cieślak M., Czarnecka J., Komoszyński M.: The purine and pirymidine nucleotides of human cerebrospinal fluid. Eur. J. Neurol. 2005; 12 (supl. 2): 172.
20. Cieślak M., Czarnecka J., Banach M., Komoszyński M.: ATP and ADP are present in cerebrospinal fluid of patients with ischemic stroke. Eur. J. Neurol. 2006; 13 (supl. 2): 61.
21. Rodríguez-Núñez A., Camiña F., Lojo S. i wsp.: Concentrations of nucleotides, nucleosides, purine bases and urate in cerebrospinal fluid of children with meningitis. Acta Paediatr. 1993; 82: 849-852.
22. Stover J., Lowitzsch K., Kempski O.S.: Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate- mediated excitotoxicity in different neurological diseases. Neurosci. Lett. 1997; 238: 25-28.
23. Dunan S., Anderson C.M., Keung E.C. i wsp.: P2X7 receptor- mediated release of excitatory amino acids from astrocytes. J. Neurosci. 2003; 23: 1320-1328.
24. Matute C., Cavaliere F.: Neuroglial interactions mediated by purinergic signalling in the pathophysiology of CNS disorders. Semin. Cell Dev. Biol. 2011; 22: 252-259.
25. Matute C.: Glutamate and ATP signalling in white matter pathology. J. Anat. 2011; 219: 53-64.
26. Abbracchio M.P., Burnstock G.: Purinoreceptors: are there families of P2X and P2Y purinoreceptors? Pharmacol. Ther. 1994; 64: 445-475.
27. Abbracchio M.P., Ceruti S.: P1 receptors and cytokine secretion. Purinergic Signal. 2007; 3: 13-25.
28. Matute C., Torre I., Pérez-Cerdá F. i wsp.: P2X7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J. Neurosci. 2007; 27: 9525-9533.
29. Zalewska-Kaszubska J.: Rola adenozyny w procesach neurodegeneracyjnych. Neurol. Neurochir. Pol. 2002; 36: 329-336.
30. Rathbone M.P., Middlemiss P.J., Gysbers J.W. i wsp.: Trophic effects of purines in neurons and glial cells. Prog. Neurobiol. 1999; 59: 663-690.
31. Ballerini P., Di Iorio P., Caciagli F. i wsp.: P2Y2 receptor upregulation induced by guanosine or UTP in rat brain cultured astrocytes. Int. J. Immunopathol. Pharmacol. 2006; 19: 293-308.
32. Lambertsen K.L., Meldgaard M., Ladeby R., Finsen B.: A quantitative study of microglial-macrophage synthesis of tumor necrosis factor during acute and late focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 2005; 25: 119-135.
33. Clausen B.H., Lambertsen K.L., Meldgaard M., Finsen B.: A quantitative in situ hybridization and polymerase chain reaction study of microglial-macrophage expression of interleukin-1β mRNA following permanent middle cerebral artery occlusion in mice. Neuroscience 2005; 132: 879-892.
34. Clausen B.H., Lambertsen K.L., Babcock A.A. i wsp.: Interleukin- 1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J. Neuroinflamation 2008; 5: 46.
35. Boutin H., LeFeuvre R.A., Horai R. i wsp.: Role of IL-1α and IL-1β in ischemic brain damage. J. Neurosci. 2001; 21: 5528-5534.
36. Lambertsen K.L., Biber K., Finsen B.: Inflammatory cytokines in experimental and human stroke. J. Cereb. Blood Flow Metab. 2012; 32: 1677-1698.
37. Maas M., Furie K.: Molecular biomarkers in stroke diagnosis and prognosis. Biomark. Med. 2009; 3: 363-383.
38. Sairanen T., Carpén O., Karjalainen-Lindsberg M.L. i wsp.: Evolution of cerebral tumor necrosis factor-α production during human ischemic stroke. Stroke 2001; 32: 1750-1758.
39. Dziewulska D., Mossakowski M.J.: Cellular expression of tumor necrosis factor and its receptors in human ischemic stroke. Clin. Neuropathol. 2003; 22: 35-40.
40. Zaremba J., Losy J.: Cytokiny w klinicznym i doświadczalnym udarze niedokrwiennym mózgu. Neurol. Neurochir. Pol. 2004; 38 (supl. 1): 57-62.
41. Zaremba J., Losy J.: Early TNF-α levels correlate with ischaemic stroke severity. Acta Neurol. Scand. 2001; 104: 288-295.
42. Zaremba J., Skrobanski P., Losy J.: Tumour necrosis factoralpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed. Pharmacother. 2001; 55: 258-263.
43. Kes V., Simundic A., Nicolac N. i wsp.: Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin. Biochem. 2008; 41: 1330-1334.
44. De Bilbao F., Arsenijevic D., Moll T. i wsp.: In vivo overexpression of interleukin-10 increases resistance to focal brain ischemia in mice. J. Neurochem. 2009; 110: 12-22.
45. Tuttolomondo A., Di Raimondo D., di Sciacca R. i wsp.: Inflammatory cytokines in acute ischemic stroke. Curr. Pharm. Des. 2008; 14: 3574-3589.
46. Biber K., Pinto-Duarte A., Wittendrop M.C.: Interleukin-6 upregulates neuronal adenosine A1 receptors: implications for neuromodulation and neuroprotection. Neuropsychopharmacology 2008; 33: 2237-2250.
47. Pizzi M., Sarnico I., Boroni F. i wsp.: Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Mol. Cell. Neurosci. 2004; 25: 301-311.
48. Nelson T.E., Netzeband J.G., Gruol D.L.: Chronic interleukin- 6 exposure alters metabotropic glutamate receptor-activated calcium signalling in cerebellar Purkinje neurons. Eur. J. Neurosci. 2004; 20: 2387-2400.
49. Conroy S., Nguyen V., Quina L. i wsp.: Interleukin-6 produces neuronal loss in developing cerebellar granule neuron cultures. J. Neuroimmunol. 2004; 155: 43-54.
50. Tarkowski E., Rosengren L., Blomstrand C. i wsp.: Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin. Exp. Immunol. 1997; 110: 492-499.
51. Beridze M., Sanikidze T., Shakarishvili R. i wsp.: Selected acute phase CSF factors in ischemic stroke: findings and prognostic value. BMC Neurol. 2011; 11: 41.
52. Montaner J., Rovira A., Molina C. i wsp.: Plasmatic level of neuroinflammatory markers predict the extent of diffusionweighted image lesions in hyperacute stroke. J. Cereb. Blood Flow Metab. 2003; 23: 1403-1407.
53. Sun Y., Lu C.J., Lin C.H., Wen L.L.: Interleukin-1β is increased in the cerebrospinal fluid of patients with small infarcts. Eur. J. Neurol. 2009; 16: 858-863.
54. Fassbender K., Rossol S., Kammer T. i wsp.: Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neurol. Sci. 1994; 122: 135-139.
55. Tarkowski E., Rosengren L., Blomstrand C. i wsp.: Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26: 1393-1398.
56. Emsley H.C., Smith C.J., Gavin C.M. i wsp.: Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol. 2007; 7: 5.
57. Waje-Andreassen U., Kråkenes J., Ulvestad E. i wsp.: IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand. 2005; 111: 360-365.
58. Becker K.: Inflammation and acute stroke. Curr. Opin. Neurol. 1998; 11: 45-49.
59. Becker K.: Targeting the central nervous system inflammatory response in ischemic stroke. Curr. Opin. Neurol. 2001; 14: 349-353.
60. Smith C., Emsley H.C., Udeh C. i wsp.: Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine 2012; 58: 384-389.
61. Ormstad H., Dalsbotten H., Lund-Sorensen A. i wsp.: Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralisation, type, and infarct volume. J. Neurol. 2011; 258: 677-685.
62. Weisman G., Camden J., Peterson T. i wsp.: P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y2 receptor interactions in neuroinflammation. Mol. Neurobiol. 2012; 46: 96-113.
63. Stoeckel M.E., Uhl-Bronner S., Hugel S. i wsp.: Cerebrospinal fluid-contacting neurons in the rat spinal cord, a γ-aminobutyric acidergic system expressing the P2X2 subunit of purinergic receptors, PSA-NCAM, and GAP-43 immunoreactivities: light and electron microscopic study. J. Comp. Neurol. 2003; 457: 159-174.
64. Czarnecka J., Roszek K., Jabłoński A. i wsp.: Some aspects of purinergic signaling in the ventricular system of porcine brain. Acta Vet. Scand. 2011; 53: 54.
65. Johansson P.A., Burnstock G., Dziegielewska K.M. i wsp.: Expression and localization of P2 nucleotide receptor subtypes during development of the lateral ventricular choroid plexus of the rat. Eur. J. Neurosci. 2007; 25: 3319-3331.
66. Kashyap R.S., Kainthla R.P., Mudaliar A.V. i wsp.: Cerebrospinal fluid adenosine deaminase activity: a complimentary tool in the early diagnosis of tuberculous meningitis. Cerebrospinal Fluid Res. 2006; 3: 5.
67. Cruz Portela L.V., Oses J.P., Silveira A.L. i wsp.: Guanine and adenine nucleotidase activities in rat cerebrospinal fluid. Brain Res. 2002; 950: 74-78.
68. Schutte C.M., Ungerer J.P., du Plessis H., van der Meyden C.H.: Significance of cerebrospinal fluid adenosine deaminase isoenzymes in tuberculous (TB) meningitis. J. Clin. Lab. Anal. 2001; 15: 236-238.
69. Di Virgilio F.: Purinergic signalling in the immune system. A brief update. Purinergic Signal. 2007; 3: 1-3.
70. Di Virgilio F., Ceruti S., Bramanti P., Abbracchio M.P.: Purinergic signalling in inflammation of the central nervous system. Trends Neurosci. 2009; 32: 79-87.
71. Bours M.J., Swennen E.L., Di Virgilio F. i wsp.: Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 2006; 112: 358-404.
72. Honda S., Sasaki Y., Ohsawa K. i wsp.: Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o- coupled P2Y receptors. J. Neurosci. 2001; 21: 1975-1982.
73. Trautmann A.: Extracellular ATP in immune system: more than a just a danger signal. Sci. Signal. 2009; 2: 1-3.
74. Perregaux D., Gabel C.A.: Interleukin-1β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 1994; 269: 15195-15203.
75. Sperlagh B., Illes P.: Purinergic modulation of microglial cell activation. Purinergic Signal. 2007; 3: 117-127.
76. Chakfe Y., Seguin R., Antel J. i wsp.: ADP and AMP induce interleukin-1β release from microglial cells through activation of ATP-primed P2X7 receptor channels. J. Neurosci. 2002; 22: 3061-3069.
77. Langston H., Ke Y., Gewirtz A. i wsp.: Secretion of IL-2 and IFN-γ but not IL-4 by antigen-specific T cells requires extracellular ATP. J. Immunol. 2003; 170: 2962-2970.
78. Carroll W.A., Donnelly-Roberts D., Jarvis M.F.: Selective P2X7 receptor antagonists for chronic inflammation and pain. Purinergic Signal. 2009; 5: 63-73.
79. John G.R., Simpson J.E., Woodroofe M.N. i wsp.: Extracellular nucleotides differentially regulate interleukin-1β signaling in primary human astrocytes: implications for inflammatory gene expression. J. Neurosci. 2001; 21: 4134-4142.
80. Gabel C.A.: P2 purinergic receptor modulation of cytokine production. Purinergic Signal. 2007; 3: 27-38.
81. Skaper S.D., Debetto P., Giusti P.: The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 2009; 24: 337-345.
82. Grahames C.B, Michel A.D., Chessell I.P. i wsp.: Pharmacological characterization of ATP- and LLPS-induced IL-1β release in human monocytes. Br. J. Pharmacol. 1999; 127: 1915-1921.
83. Lister M.F., Sharkey J., Sawatzky D.A. i wsp.: The role of purinergic P2X7 receptor in inflammation. J. Inflamm. (Lond.). 2007; 4: 5.
84. Hughes J.P., Hatcher J.P., Chessell I.P.: The role of P2X7 in pain and inflammation. Purinergic Signal. 2007; 3: 163-169.
85. Colomar A., Marty V., Médina C. i wsp.: Maturation and release of interleukin-1β by lipopolysaccharide-primed mouse Schwann cells require the stimulation of P2X7 receptors. J. Biol. Chem. 2003; 278: 30732-30740.
86. Narcisse L., Scemes E., Zhao Y. i wsp.: The cytokine IL-1β transiently enhances P2X7 receptor expression and function in human astrocytes. Glia 2005; 49: 245-258.
87. Yegutkin G.G.: Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 2008; 1783: 673-694.
88. Schnurr M., Toy T., Shin A. i wsp.: Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 2005; 105: 1582-1589.
89. Gessi S., Varani K., Merighi S. i wsp.: Adenosine and lymphocyte regulation. Purinergic Signal. 2007; 3: 109-116.
90. Robson S.C., Sévigny J., Zimmermann H.: The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2006; 2: 409-430.
91. Friedle S.A., Curet M.A., Watters J.J.: Recent patents on novel P2X7 receptor antagonists and their potential for reducing central nervous system inflammation. Recent Pat. CNS Drug Discov. 2010; 5: 35-45.
92. Pulte E.D., Broekman M.J., Olson K.E. i wsp.: CD39/NTPDase- 1 activity and expression in normal leukocytes. Thromb. Res. 2007; 121: 309-317.
93. Dwyer K.M., Deaglio S., Gao W. i wsp.: CD39 and control of cellular immune responses. Purinergic Signal. 2007; 3: 171-180.
94. Kukulski F., Komoszyński M.: E-NTPDazy - enzymy uczestniczace w procesach sygnalizacji w centralnym układzie nerwowym. Postepy Biol. Komórki 2002; 3: 449-463.
95. Braun N., Lenz C., Gillardon F. i wsp.: Focal cerebral ischemia enhances glial expression of ecto-5'-nucleotidase. Brain Res. 1997; 766: 213-226.
96. Haskó G., Pacher P., Vizi E.S., Illes P.: Adenosine receptor signaling in the brain immune system. Trends Pharmacol. Sci. 2005; 26: 511-516.
97. Baxter A., Bent J., Bowers K. i wsp.: Hit-to-lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003; 13: 4047-4050.
98. Romagnoli R., Baraldi P.G., Di Virgilio F.: Recent progress in the discovery of antagonists acting at P2X7 receptor. Expert Opin. Ther. Pat. 2005; 15: 271-287.
99. Merriman G.H., Ma L., Shum P. i wsp.: Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonist. Bioorg. Med. Chem. Lett. 2005; 15: 435-438.
100. Conigrave A.D., Fernando K.C., Gu B. i wsp.: P2Y11 receptor expression by human lymphocytes: evidence for two cAMP-linked purinoceptors. Eur. J. Pharmacol. 2001; 426: 157-163.
101. Ecke D., Fischer B., Reiser G.: Diastereoselectivity of the P2Y11 nucleotide receptor: mutational analysis. Br. J. Pharmacol. 2008; 155: 1250-1255.
102. Vitiello L., Gorini S., Rosano G., la Sala A.: Immunoregulation through extracellular nucleotides. Blood 2012; 120: 511-518.
103. Marteau F., Communi D., Boeynaems J.M., Suarez Gonzalez N.: Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on human monocyte-derived dendritic cells. J. Leukoc. Biol. 2004; 76: 796-803.
104. Nowak J.Z., Zawilska J.B. (red.): Receptory i mechanizmy przekazywania sygnału. PWN, Warszawa 2004.
105. Wang L., Jacobsen S.E., Bengtsson A., Erlinge D.: P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 2004; 5: 16.
106. Inoue K.: The function of microglia through purinergic receptors: neuropathic pain and cytokine release. Pharmacol. Ther. 2006; 109: 210-226.
107. Sitkovsky M.V., Ohta A.: The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. 2005; 26: 299-304.
108. Matzinger P.: The danger model: a renewed sense of self. Science 2002; 296: 301-305.
109. Cieślak M., Kukulski F., Komoszyński M.: Emerging role of extracellular nucleotides and adenosine in multiple sclerosis. Purinergic Signal. 2011; 7: 393-402.